BRCA2 and ovarian cancer: Given that we did not observe upregulation of Tcf1/7, Myc, and cyclin D1 in BRCA2-null ovarian cancer cells, the potential absence of these prosurvival mechanisms may very well contribute to the improved survival observed in patients with BRCA2 ovarian cancer (15).